Novel uses of thyroid hormones in cardiovascular conditions by Razvi S
Endocrine (2019) 66:115–123
https://doi.org/10.1007/s12020-019-02050-4
REVIEW
Novel uses of thyroid hormones in cardiovascular conditions
Salman Razvi 1
Received: 9 July 2019 / Accepted: 5 August 2019
© The Author(s) 2019
Abstract
Thyroid hormone levels are reduced in cardiovascular diseases and this phenomenon is associated with worse outcomes. It is
unclear whether the changes in thyroid hormone bioavailability to the affected myocardium are beneficial or if this is a
maladaptive response. Experimental studies from animal models of acute myocardial infarction (AMI) suggest that thyroid
hormone treatment may be beneficial. There is limited data available on the use of thyroid hormones in patients with AMI
and heart failure and this suggests that treatment to normalise thyroid hormone levels may be safe and potentially efficacious.
Similarly, evidence of thyroid hormone therapy in patients undergoing cardiac surgery or during cardiac transplantation is
limited. It is therefore difficult to draw any firm conclusions about benefits or risks of thyroid hormone treatment in these
conditions. Large scale clinical trials of thyroid hormones in patients with cardiac conditions are required to confirm safety
and evaluate efficacy. Furthermore, it needs to be elucidated which hormone to administer (thyroxine or triiodothyronine),
when in the disease pathway to treat, dose of thyroid hormone to administer, and which parameters to utilise to assess safety
and efficacy. Until these important questions are answered thyroid hormone therapy in cardiovascular diseases must remain
within the research domain.
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Introduction
Over the course of the last few decades changes in lifestyle
have led to increases in atherosclerotic conditions, such as
obesity, hypertension, and type 2 diabetes mellitus. These
lifestyle-related morbidities together with an increased
lifespan has caused a steep rise in the incidence and pre-
valence of cardiovascular diseases (CVD). CVD, of which
ischaemic heart disease is the predominant condition,
affects hundreds of millions of individuals across the world
[1]. Behavioural changes, therapeutic targeting of CVD risk
factors, and improvements in the management of acute
coronary events have slowed the increase in CVD overall
but has led to increases in chronic health conditions and
health-related spending [2]. For instance, the reduction in
short-term mortality after acute coronary events has resulted
in an increased burden of longer-term sequelae such as heart
failure. Newer therapies are required to alleviate the pro-
blem of CVD on a global scale in a cost-effective manner.
Thyroid hormones regulate development and metabolism
of various organs with the cardiovascular system being a
major target for its actions [3]. Minor changes in thyroid
hormones, even within the reference range, are associated
with increased risk of CVD and cardiovascular risk factors
[4]. Thus, it is possible that modulating thyroid hormone
levels could be utilised as a therapeutic option to improve
health. In addition, illness itself can lead to reversible
changes in thyroid function—a process termed as non-
thyroidal illness (NTI). The perturbations in thyroid func-
tion in NTI are not directly attributed to primary hypotha-
lamic, pituitary, or thyroid diseases [5]. It has been debated
for some time whether the changes in thyroid function
observed in NTI are protective as they minimise protein
catabolism, or whether they represent pathological thyroid
hormone deficiency that could potentially benefit from
hormone replacement therapy. The argument centres around
the crucial effects of thyroid hormones on processes
involved in repair mechanisms. Thyroid hormone
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deficiency could lead to a number of cardiovascular effects
including decreased cardiac output, increased systemic
vascular resistance, or delayed repair from injury, and
immune dysfunction [6]. Unnecessary thyroid hormone
replacement, on the other hand, increases oxygen demand
and cardiac work and induces tachyarrhythmias, particularly
atrial fibrillation, coronary spasm, and cardiac ischaemia
even in the absence of significant coronary artery disease
[5]. As the heart and vascular system are important target
organs of thyroid hormone action this review will focus on
novel uses of thyroid hormone in cardiovascular conditions.
Historical perspective on the use of thyroid
hormones in CVD
Thyroid extract was the first hormonal preparation intro-
duced into clinical medicine more than a century ago. In
1891, George Murray, a pathologist in Newcastle, England,
injected sheep thyroid extract subcutaneously to a 46-year-
old woman with typical clinical features of myxoedema [7].
The clinical effect was swift and very effective, and the
patient went on to live for almost 30 years on thyroid
hormone substitution therapy and eventually died of heart
failure [8]. Edward Kendall crystallised thyroxine (T4) in
1914 and Harington and Barger identified its chemical
structure and synthesised it in the laboratory in 1927 [9].
Subsequently, Pitt-Rivers and Gross detected the second
thyroid hormone triiodothyronine (T3) [10]. Treatment with
injectable and then oral thyroid extract remained the
mainstay of treatment until the 1950s probably due to the
high cost of the synthetic levothyroxine [11]. Later, as
levothyroxine became more widely available at reasonable
cost the use of thyroid extract became virtually non-
existent. In addition, there have been concerns about the
ratio of T3:T4 in the porcine-derived thyroid extract which
is much higher than the amount secreted by the human
thyroid gland [12].
When the striking effects of thyroid hormones on serum
cholesterol levels became apparent, cholesterol determina-
tion and measurement of basal metabolic rate were utilised
as indirect diagnostic tests of thyroid function, particularly
in the absence of specific hormonal assays of thyroid
function [9]. Furthermore, atherosclerosis of peripheral
arteries was found to be associated with low protein-bound
iodine and low basal metabolic rate, both suggestive of
hypothyroidism [13]. In addition, postmortem analysis of
patients who died of heart attacks revealed morphologic
changes indicative of thyroid hormone deficiency [14].
Thus, it was not surprising that researchers started con-
sidering thyroid hormone therapy as a therapeutic agent in
treating CVD.
Enthusiasm for the use of thyroid hormone therapy in
CVD was however curbed when it was observed that patients
with angina often experienced an increase in symptoms even
when physiological doses of thyroid extract were used,
especially if therapy was started abruptly. Therefore, it
became standard clinical practice to start with low doses and
to increase the hormone gradually. It was also believed that
synthetic isomer D-thyroxine might be superior to L-thyroxine
(the synthetic form of the natural hormone) in decreasing
serum cholesterol levels without increasing myocardial
oxygen demand [15]. But, a double-blind trial lasting 5 years,
the Coronary Drug Project, in patients with a history of
myocardial infarction, showed that mortality from the cor-
onary heart disease was similar in the group treated with
D-thyroxine compared to the group treated with placebo [16].
It was however noted that the D-thyroxine group experienced
remarkably more proarrhythmic effects. This worrying side-
effect was probably due to the fact that the dose of D-thyr-
oxine administered (6 mg/day) was equivalent to more than
300mg of L-thyroxine [17]. In addition, the D-thyroxine
preparation used in the trial was contaminated with a high
level of active L-thyroxine [18]. Thus, the trial was termi-
nated early and never repeated again.
More recently, data from experimental studies and epide-
miological observations have shown that thyroid dysfunction
is associated with higher cardiovascular morbidity and mor-
tality [19–21]. Furthermore, even variations of thyroid hor-
mones within the reference range have been linked with
adverse events. Therefore, interest in the use of thyroid hor-
mones in the management of CVD has been reawakened.
Pathophysiology of TH changes in cardiac
conditions
The two main thyroid hormones T4 and T3 are secreted by
the thyroid gland in response to stimulation by thyroid sti-
mulating hormone (TSH). Both T4 and T3 have biological
actions but T3 is considered the active hormone. Thyroid
hormone metabolism is regulated by enzymes called deio-
dinases. Type I (DIO1) and type II iodothyronine deiodi-
nase (DIO2) lead to extrathyroidal T3 production from the
precursor T4. DIO1, which is active in the liver and kidney,
produces 15–20% of total circulating T3, whereas DIO2
activity located in the pituitary, brain, brown adipose tissue,
and heart is responsible for the remaining two-thirds of T3
production [22–24]. DIO3, on the other hand, catabolizes
both thyroid hormones and terminates their action. The
thyroid hormone status of any given tissue is dependent on
both circulating as well as intracellular thyroid hormone
levels, which are regulated by deiodinases and thyroid
hormone transporters.
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Thyroid hormones have wide-ranging effects on the
cardiovascular system (see Fig. 1). Thyroid hormones
influence cardiac status by several mechanisms: by direct
genomic actions through binding to nuclear receptors
leading to the regulation of the expression of target genes in
the cardiomyocyte; by extranuclear, nongenomic actions on
the ion channels located in the cardiomyocyte cell mem-
brane; and through effects of both thyroid hormones on the
peripheral circulation [3].
In the nucleus of the cardiomyocyte, T3 binds to thyroid
hormone receptors (TR), which in turn bind to thyroid
hormone response elements in the regulatory regions of
target genes to control transcription. The two main TRs are
TRα, which is highly expressed in cardiomyocytes, and
TRβ. TRs can bind to thyroid hormone response elements
even in the absence of thyroid hormones, leading to
repression of transcription of target genes. Thus, gene reg-
ulation in the cardiomyocyte is dependent on the avail-
ability of thyroid hormones [25]. Thyroid hormones
regulate myocardial contractility and systolic function by
activation of genes encoding sodium/potassium-transport-
ing ATPases, myosin heavy chain-α, and sarcoplasmic/
endoplasmic reticulum calcium ATPase 2, and negatively
regulating the transcription of myosin heavy chain-β and
phospholamban [3]. Thyroid hormones also have a direct
inotropic effect on the heart by positively regulating the
gene expression of the β1-adrenergic receptor [26]. In
addition, thyroid hormones influence cardiac chronotropy
through both genomic and nongenomic effects on compo-
nents of the adrenergic-receptor complex and on sodium,
potassium, and calcium ion channels [27]. The nongenomic
effects of thyroid hormones on cardiomyocytes and the
vascular system include activation of sodium, potassium,
and calcium membrane ion channels, effects on the mito-
chondrial membrane and mitochondriogenesis, and invol-
vement in signalling pathways of cardiomyocytes and
vascular smooth muscle cells [3].
In cardiac diseases, such as heart failure or acute myo-
cardial infarction, the intracellular cardiomyocyte environ-
ment is affected by hypoxia, which in turn leads to
inflammation [28]. The hypoxia and the resultant inflam-
matory response reduce deiodinase activity in the cardio-
myocyte, which along with reduced plasma T3 levels, result
in a decrease in intracellular T3 bioavailability (see Fig. 2).
Furthermore, increased DIO3 gene expression under
hypoxic conditions leads to degradation of T3 into inactive
metabolites. Therefore, the intracellular environment in the
cardiomyocyte in a number of cardiac conditions presents
with reduced availability of T3 and, consequently, reduced
metabolism. The clinical implications of the reduced bioa-
vailability of thyroid hormones in these patients is unclear.
There are remarkable similarities between developmental
processes and changes occurring in the damaged myo-
cardium, which has refocused research on the role of thyr-
oid hormones in the pathophysiology of cardiac disease.
Disparate stressful processes such as pressure overload,
hypoxia, ischaemia, inflammation, and metabolic dis-
turbances result in the predominance of the foetal gene
programming. This genetic developmental switch of the
diseased myocardium is not well understood [29]. However,
recent evidence suggests that reactivation of the foetal
genotype may constitute a permissive state for cell
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Fig. 1 Thyroid hormone actions on the cardiomyocyte Thyroid hor-
mones T4 (thyroxine) and triiodothyronine (T3) enter the cardio-
myocyte via plasma membrane transporters. Inside the myocardial
cell, T4 can be activated by the enzyme DIO2 (deiodinase 2) to the
active form T3, and both T4 and T3 can be inactivated by DIO3
(deiodinase 3) to rT3 (reverse T3) and T2 (diiodothyronine),
respectively. From the cytosol T3 diffuses into the nucleus and binds
to thyroid hormone receptors (TR) in the presence of TRE (thyroid
hormone response elements) and initiates the regulation of target genes
and other metabiolic pathways (genomic actions). In addition, thyroid
hormones also have direct nongenomic actions. Adapted from Jabbar
et al. [3]
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regeneration. There is some evidence that thyroid hor-
mones, which play a critical role during development, may
also have an important function in regeneration and repair
during adult life [30, 31]. Thus, thyroid hormones may have
important therapeutic potential in the management of a
number of cardiac conditions.
Thyroid hormones in heart failure
Thyroid hormones have multiple effects on the cardiovas-
cular system, ranging from molecular and cellular effects to
consequent hemodynamic alterations. There is increasing
evidence that suggests an adverse relationship between
thyroid dysfunction and heart failure (Table 1). In patients
with heart failure, both low and high serum TSH levels are
associated with higher mortality [32]. Furthermore, higher
serum TSH levels are a strong and independent predictor of
clinical outcomes including death and cardiac-related hos-
pitalisations [32]. In the SCD-HeFT trial increased serum
TSH levels were related to higher mortality in patients with
impaired left ventricular systolic function [33]. The other
common biochemical abnormality observed in nearly one-
third of patients with heart failure is the so-called “Low T3
Syndrome” [34].
The physiological reasons for the development of a low
T3 state in patients with severe illness and, in particular,
with heart failure, are not clearly understood. There are at
least three potential mechanisms that may explain the
development of the low circulating T3 levels in patients
with moderate and severe heart failure:
(1) Reduced activity of DIO1 and DIO2: a decreased
extrathyroidal conversion of T4 to T3 due to diminished
activity of peripheral deiodinases, associated with a
decreased transport of T4 into tissues [35, 36].
(2) Increased DIO3 activity: an increase in peripheral
thyroid hormone break-down due to an ectopic
induction of DIO3 activity in peripheral tissues leading
to increased reverse T3 levels I [37].
(3) Central hypothyroidism: decreased plasma levels of
TSH and by the concomitant abnormalities in thyro-
tropin releasing hormone [38].
The increased levels inflammatory proteins such as
interleukins and cytokines (IL-6, TNF-α, etc.) observed in
patients with severe heart failure is associated in both
experimental models and clinical scenarios with a pattern
similar to low T3 state [39–42]. This observation supports
the hypothesis of a link between neuroendocrine and
proinflammatory pathways. Moreover, in addition to the
above-mentioned changes in hormonal, deiodinase and
inflammatory processes, abnormalities in TRs expression in
patients with heart failure is also a contributory factor in the
development of tissue hypothyroidism [43, 44]. In a rat
model of hypothyroidism, T4 replacement therapy nor-
malises plasma thyroid hormone levels, but does not reverse
the associated cardiac and vascular changes, suggesting that
serum thyroid hormone levels may not accurately reflect
tissue thyroid status [45].
The increased cardiac risk in patients with heart failure
and low T3 syndrome offers a mechanistic basis for thyroid
hormone therapy in patients with left ventricular dysfunc-
tion and low/borderline levels of serum T3. In this group of
patients, restoration of normal thyroid hormone levels could
positively re-establish myocardial gene expression, improve
cardiac function and haemodynamics, and thus alleviate
morbidity and mortality. A few clinical trials of thyroid
hormones have been conducted in patients with heart fail-
ure. Moruzzi et al. demonstrated that short- and medium-
term levothyroxine therapy in a small number of patients
with idiopathic dilated cardiomyopathy (NYHA class
II–IV) improved cardiac function and exercise performance,
without any significant side effects [46, 47]. In another trial,
23 patients with advanced heart failure (NYHA class
III–IV) who were treated with short-term intravenous T3
Acute myocardial infarcon
Reducon in circulang T3 levels
Reducon in intramyocardial ssue T3 levels
Thyroid hormone metabolism
Increased DIO3 acvity
Reduced DIO2 effects
Thyroid hormone receptors
Unliganded TR 1
Repress transcripon of thyroid 
hormone mediated genes
Intra-cardiomyocyte hypothyroid state
Fig. 2 Effects of low serum T3 levels in acute myocardial infarction
T3—triiodothyronine, DIO3—deiodinase 3, DIO2—deiodinase 2,
TR—thyroid hormone receptor
Table 1 Effects of thyroid hormone T3 on various cardiovascular and
neuroendocrine parameters in patients with heart failure
Parameter and effect
Left ventricular systolic function ⇑
Left ventricular diastolic function ⇑
Systemic vascular resistance ⇓
Noradrenaline ⇓
Aldosterone ⇓
Natriuretic peptide synthesis ⇑
Myocardial blood flow ⇑
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administration at supra-physiological doses showed an
improvement in cardiac output and a reduction in systemic
vascular resistance, without significant changes in blood
pressure or heart rate [48]. Pingitore et al. randomised 20
patients with heart failure and low T3 levels to treatment
with T3 infusion for 3 days at physiological doses or pla-
cebo [49]. In this trial, normalising circulating T3 levels
were associated with increases in parameters of left ven-
tricular function. In addition, there appeared to be a neu-
roendocrine reset, with significant decreases in
norepinephrine, aldosterone and NT-pro BNP plasma levels
[49]. A trial of oral T3 or placebo in 13 patients with stable
heart failure and low T3 levels failed to show a significant
benefit after 6 months of therapy though [50]. The largest
placebo-controlled trial to date of oral T3 in 50 patients with
mild to moderate (NYHA class I–III) heart failure and low
T3 levels demonstrated benefits in left ventricular function,
exercise performance as well as improvement in inflam-
matory markers [51].
Despite these results, the small number of patients stu-
died, the relatively short duration of treatment, and differ-
ences in the route and dose of T3 used, limit interpretation
of results. Nonetheless, these results suggest that T3 therapy
in patients with stable chronic heart failure may be bene-
ficial. Larger multicentre trials for longer periods that also
provide information on hard clinical outcomes such as
mortality, arrhythmias, and hospitalisations are required
before thyroid hormone therapy can be routinely prescribed
in patients with heart failure as part of clinical practice.
Thyroid hormones in acute myocardial
infarction
Thyroid hormone action is important for myocardial con-
tractility, acts as a vasodilator and has a direct positive
action on myocardial mitochondrial function. Furthermore,
antiaptotic and antifibrotic effects of thyroid hormones
may also attenuate maladaptive cardiac remodelling and
improve myocardial function post-AMI. Reduction in
concentration of the active thyroid hormone T3 in
ischaemic cardiomyocytes has also been linked to the
pathogenesis of ischaemia-reperfusion injury [52]. In
rodent models of AMI, a state of tissue hypothyroidism is
observed, independently of circulating T3 levels [53]. In
AMI patients undergoing reperfusion therapy, subsequent
reduction in circulating T3 levels represents a strong
independent predictor of death and major adverse cardiac
events [54]. In addition, subclinical hypothyroidism in
cardiac patients is associated with poor prognosis [55].
Therefore, thyroid hormone therapy in AMI patients may
offer a potentially useful option to limit ischaemia-
reperfusion injury and reduce infarct size, and also
improve postinfarct left ventricular function as well as
morbidity and mortality.
Data from experimental studies
Thyroid hormones have several effects on the cardiovas-
cular system that are relevant to the pathophysiology of the
injured cardiomyocyte after an AMI. T3 plays a critical role
in regulating mitochondrial function and morphology,
modulating antifibrotic and proangiogenic effect, and also
by impacting on cell regeneration and repair [3]. Numerous
studies in animal models of AMI have shown that thyroid
hormone treatment commenced a few hours to a week after
AMI limits ischaemia-reperfusion injury and increases post-
ischaemic myocardial functional recovery [56, 57]. This
effect seems to be of therapeutic relevance for supporting
haemodynamics in the clinical setting of ischaemia-reper-
fusion, such as myocardial infarction or cardiac surgical
procedures.
Thyroid hormones are essential in the regulation of
molecular mechanisms of angiogenesis, cardioprotection,
cardiac metabolism, and myocyte regeneration—processes
that can modulate recovery from injury and left ventricular
remodelling. Based on experimental studies, the protective
effect of thyroid hormone on reducing ischaemic reperfu-
sion injury and improving cardiomyocyte remodelling and
function is considered to be mediated by:
Antiapoptotic and mitochondrial protection by modulat-
ing mitochondrial permeability transition pore (MPTP)
opening [58–60].
Positive effects on the thyroid hormone deactivating
enzyme DIO3, MCT-10 (thyroid hormone transporter)
and foetal gene re-expression, and thus restoring
cardiomyocyte T3 levels [28].
Attenuates infarct fibrotic area and reverses foetal gene
expression [61].
Improved myocyte preservation in the peri-infarct zone
[62].
Facilitate recovery of stunned myocardium and left
ventricular function with positive effects on alpha- and
beta-myosin heavy chain (MHC) and SERCA/Phospho-
lamban ratios [63, 64].
Data from clinical observations and trials
There have been a number of studies in patients with AMI
that have evaluated T3 levels with morbidity and mortality
[65]. Most studies have reported an adverse association
between low circulating T3 and all-cause mortality, troponin
levels, myocardial area at risk, or cardiovascular complica-
tions. These observations, however, cannot ascertain a causal
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association between the two conditions, and, therefore,
interventional trials of T3 are required to investigate the link.
There is little data on the safety and efficacy of T3 in AMI
patients apart from a recent phase II trial [66]. In this ran-
domised controlled trial of oral T3 in 37 patients with STEMI
and low serum FT3 levels, T3 replacement therapy for
6 months was shown to be safe and effective in reducing
regional cardiac dysfunction. Left ventricular ejection frac-
tion and myocardial infarct size, as assessed by cardiac MRI,
did not show any benefit. In this trial, T3 therapy was
commenced 72 h after the onset of STEMI, and the pre-
paration was administered three times per day. This small
trial provides reassurance that normalisation of serum T3
levels in patients with STEMI who have low circulating T3
levels is safe, if T3 therapy is comenced a few days after the
acute event. Another trial of levothyroxine in AMI patients
with subclinical hypothyroidism is ongoing with the aim to
evaluate effects on left ventricular function [67]. However,
trials of thyroid hormones in AMI in larger groups of patients
and treated for longer duration are required to confirm safety
and efficacy before thyroid hormone supplementation can be
considered for routine use in these patients.
Thyroid hormones in cardiac surgery and
cardiac transplantation
There are several trials of thyroid hormones, particularly
T3, in other cardiac conditions that provide useful infor-
mation and help to draw valuable conclusions. T3 admin-
istration in patients undergoing cardiac surgery such as
coronary artery bypass grafting, a procedure in which
myocardial tissue is subjected to ischaemia-reperfusion
injury, reduces troponin release and improves post-surgery
haemodynamics [68]. Similarly, thyroid hormone adminis-
tration in children undergoing surgery for congenital heart
defects protects against myocardial ischaemia-reperfusion
injury [69]. Subgroup analysis of a large randomised clin-
ical trial (TRICC) showed a significant reduction in extu-
bation time and use of inotropic drugs, and better cardiac
function with T3 supplementation after surgery in paediatric
patients aged <5 months [70].
Thyroid hormone use can have important implications
for organ selection and cardiac function before and after
transplantation. Experimental studies demonstrated a surge
of adrenaline levels after the induction of brain death in a
baboon, which was associated with rapid declines in
plasma levels of various hormones including T4 and T3
[71]. The reduction in thyroid hormone levels after brain
death can lead to significant impairment of cardiovascular
function partly due to impairment in aerobic respiration
[72, 73]. Hormonal therapy that included T3 in a series of
brain-dead potential organ donors resulted in improved
outcomes. A retrospective analysis of more than 66,000
brain-dead potential organ donors in the USA revelaed that
thyroid hormone therapy increased in the number of
transplantable organs by nearly 13% [73]. A survey of 24
organ procurement organisations in the USA showed that
more than 70% utilise thyroid hormones in all potential
donors although there is large variation in the dose used
[74]. A consensus statement by opinion leaders recom-
mended the use of hormonal resuscitation, including T3, to
maximise use of potential organs [75].
Conclusion
Current experimental and clinical evidence suggests that
thyroid hormone treatment may be beneficial in improving
cardiac function and that risks of arrhythmias appear to be
low. However, despite encouraging indications from experi-
mental studies, large adequately-powered interventional trials
of thyroid hormones in patients with various cardiac condi-
tions have not been conducted. One explanation for this is the
common belief of physicians that exogenous thyroid hormone
(or its analogues) therapy in cardiac patients could precipitate
development of arrhythmia, myocardial ischaemia/ infarction,
or worsening of congestive heart failure.
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